Literature DB >> 12203197

Pathogenesis of parathyroid dysfunction in end-stage renal disease.

Justin Silver1.   

Abstract

The parathyroid functions to maintain normal calcium and phosphate homeostasis and is central to normal bone physiology. In end-stage renal disease (ESRD), there is a failure of these normal homeostatic mechanisms with the frequent development of secondary hyperparathyroidism, which contributes to the pathogenesis of renal bone disease. The phosphate retention of ESRD, together with the reduced serum calcium and 1,25-dihydroxycholecalciferol vitamin D(3) (1,25[OH](2)D(3)) concentrations are the known factors that determine the progression to secondary hyperparathyroidism. 1,25(OH)(2)D(3) markedly decreases parathyroid hormone (PTH) gene transcription, whereas the effects of calcium and phosphate are on PTH mRNA stability, PTH secretion, and parathyroid cell proliferation. The mechanisms of these effects are discussed in this review. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203197     DOI: 10.1053/jarr.2002.34846

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  4 in total

1.  Assessment of parathyroid glands in hemodialysis patients by using color Doppler sonography.

Authors:  Umit Aksoy Ozcan; Ilay Oktay
Journal:  Eur Radiol       Date:  2009-05-27       Impact factor: 5.315

2.  Cox-2 expression in the oxyphilic cells of the normal, hyperplastic, and adenomatous parathyroid gland.

Authors:  C David Bell; Sergio Vidal; Kalman Kovacs; Jennifer Anderson; Fabio Rotondo
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 3.  Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease.

Authors:  Yi-Chou Hou; Cai-Mei Zheng; Hui-Wen Chiu; Wen-Chih Liu; Kuo-Cheng Lu; Chien-Lin Lu
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-31

4.  Recurrent calcinosis in consecutively transplanted kidney grafts.

Authors:  Otmar Janko; Jan Zazgornik; Georg Biesenbach
Journal:  Wien Klin Wochenschr       Date:  2003-09-30       Impact factor: 2.275

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.